Replies to post #5917 on Dendreon Corp fka DNDNQ

[RonnieD]

I guess it's safe to say the survival rate of this trial is 22% or higher, otherwise why would they bother.


The data to be presented are from a late-stage clinical trial and, if positive, would provide a basis for potential FDA approval of Provenge. The result could be presented the end of this month at the AUA's annual meeting in chicago if they are ready in time.